Drug Profile
HP 802247
Alternative Names: Allogeneic human skin replacement - Smith & Nephew Biotherapeutics; Allox™; DFB Healthpoint allogeneic human skin replacement; HP-802247; Human skin replacement - Smith & Nephew BiotherapeuticsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Healthpoint
- Developer Smith & Nephew Biotherapeutics
- Class Cell therapies; Skin disorder therapies
- Mechanism of Action Fibrinogen replacements; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Leg ulcer; Wounds
Most Recent Events
- 23 Feb 2015 Smith & Nephew terminate a phase III trial in Leg ulcer in Czech Republic, Poland, Hungary, Belgium and Germany due to the outcome of previous study (NCT01853384)
- 16 Jan 2015 Smith & Nephew terminates phase II trial in Leg ulcer in USA (NCT02154087)
- 01 Dec 2014 Healthpoint completes a phase III trial for Leg ulcer in USA and Canada (NCT01656889)